Evaluate the Levels of Fas‐associated Factor 1 and the Oxidation State of Breast Cancer Women
DOI:
https://doi.org/10.54153/sjpas.2024.v6i4.713Keywords:
Breast cancer, FAS-Associated Factor 1, Uric Acid, , Glutathione Peroxidase, MalondialdehydeAbstract
The current study aims to evaluate the levels of Human FAS-Associated Factor 1-FAF1, Uric Acid-UC, Glutathione Peroxidase-GPX and Malondialdehyde-MDA in sera of women with breast cancer-BC, ninety serum samples were collected from women, It was divided into 3 groups, the control group-C includes 30 samples of healthy women with no history of breast cancer, 30 samples of women newly diagnosed with breast cancer (as first group-G1), and 30 samples of women with breast cancer who underwent chemotherapy (as second group-G2). The study includes the determination of the level of serum FAF1, UA, GPX and MDA.
The results indicate that the value of body mass index-BMI and UA level were significantly (P ≤0.05) increased in G1 as compared with G2 and C. While the levels of FAF1 and MDA were significantly(P ≤0.05) elevated in the patients' group as compared with C, with no significant (P ≤0.05) difference for serum GPX activity between patients and control group.
We can conclude from the results of current study, that the FAF1, and MDA were associated with an increased risk of breast cancer. Also UA plays an important role in the development of breast cancer
Downloads
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright Notice
Authors retain copyright and grant the SJPAS journal right of first publication, with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in Samarra Journal of Pure and Applied Science.
The Samarra Journal of Pure and Applied Science permits and encourages authors to archive Pre-print and Post-print items submitted to the journal on personal websites or institutional repositories per the author's choice while providing bibliographic details that credit their submission, and publication in this journal. This includes the archiving of a submitted version, an accepted version, or a published version without any Risks.
